J. R. Hyde, III, Chairman. Mr. Hyde, age 68, has served as the Chairman of our Board of Directors since November 2000. Mr. Hyde currently serves as Chairman of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee. Since 1989, Mr. Hyde has been the sole stockholder and President of Pittco Holdings, Inc., a private, institutional investment company. Since 1996, when Mr. Hyde made a substantial contribution to support Dr. Steiner’s research, Mr. Hyde has been instrumental in forming and financing GTx and is our largest stockholder. Mr. Hyde was the Chairman of the Board of Directors of AutoZone, Inc. (NYSE: AZO) from 1986 to 1997 and the Chief Executive Officer of AutoZone from 1986 to 1996. He was also Chairman and Chief Executive Officer of Malone & Hyde, Inc., AutoZone’s former parent company, from 1972 until 1988. Mr. Hyde is a director of AutoZone, Inc. and FedEx Corporation (NYSE: FDX). From March 2005 to June 2007, Mr. Hyde was appointed as the non-executive Chairman of the Board of Directors of AutoZone, Inc.
Mitchell S. Steiner, M.D., F.A.C.S., Vice Chairman and Chief Executive Officer. Dr. Steiner, age 50, a co-founder of GTx, has served as the Vice Chairman of our Board of Directors and our Chief Executive Officer since the Company's inception in September 1997. From 1995 to 2003, Dr. Steiner held numerous academic appointments, including Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee. Since 2003, Dr. Steiner has continued to serve on the faculty at the University of Tennessee. Dr. Steiner holds a B.A. in Molecular Biology from Vanderbilt University, an M.D. from the University of Tennessee and performed his surgery and urologic training at The Johns Hopkins Hospital.
Barrington Furr, Ph.D. . Dr. Furr, age 67, was appointed to the Board of Directors in January 2011 and currently serves on the Nominating and Corporate Governance Committee. Dr. Furr holds a Ph.D. in Reproductive Endocrinology from the University of Reading (United Kingdom). From 1972 to 2005, he worked for AstraZeneca and its predecessor companies. Following the 1999 merger of Zeneca with Astra, Dr. Furr was appointed Chief Scientist and Head of Project Evaluation at AstraZeneca, where he continues his affiliation as a consultant. Dr. Furr also serves as a non-executive director of the Medicines and Healthcare products Regulatory Agency (MHRA) of the Department of Health of the United Kingdom, and also serves as a non-executive director of the leading international animal genetics company, Genus plc. Dr. Furr has been recognized extensively for his work on Zoladex®, the LHRH agonist for the first line treatment of advanced prostrate cancer, and Casodex®, the largest selling anti-androgen in the United States, Europe and Japan. He was awarded the Society for Drug Research Drug Discovery Award and the Jubilee Medal of the Society of Endocrinology. For his services to cancer drug discovery, he was made an Officer of the Order of the British Empire in January 2000. Dr. Furr was added to the Board to bolster the Board’s expertise in drug development, particularly with respect to therapies for treating prostate cancer, which is a significant focus for GTx. Additionally, Dr. Furr’s work with MHRA is expected to provide GTx with better insight and understanding of European regulatory requirements for drug development as we plan for and potentially initiate clinical studies outside of the United States.
Michael G. Carter, M.D., age 73, was appointed to the Board of Directors in May 2006 and is a member of the Compensation Committee. Dr. Carter currently is a non-executive director of Micromet, Inc. and Santarus, Inc. He was non-executive chairman of Metris Therapeutics, Ltd., a biotechnology firm specializing in women's healthcare from 1999-2008. He is a member of the Advisory Board of Paul Capital Royalty Fund from 2005 to 2008 and has been a venture partner with SV Life Sciences Advisers, LLP since 1998. He served on the Pharmaceutical Board of Zeneca Pharmaceuticals, a predecessor company of AstraZeneca, and held various positions within Zeneca, including International Marketing Director and International Medical Director. Under his direction, Zeneca developed and launched numerous drugs, including Casodex®, the most widely prescribed anti-androgen for prostate cancer therapy in the U.S.; Zoladex®, an LHRH analogue for prostate cancer and breast cancer; and Arimidex®, the first new generation aromatase inhibitor for breast cancer. Dr. Carter also contributed to the post marketing development of tamoxifen, the first selective estrogen receptor modulator approved for the treatment of breast cancer. Dr. Carter received his medical degree from Sheffield University Medical School and a BPharm degree from the London University School of Pharmacy. He is a Fellow of the Royal Pharmaceutical Society, of the Royal College of Physicians of Edinburgh and of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He has served as a member of the Medicines Commission of the United Kingdom
J. Kenneth Glass, age 64, has served as a director since March 2004 and currently serves on the Audit Committee as Chairman and on the Compensation Committee. Mr. Glass was until 2007, Chairman of the Board, President and Chief Executive Officer of First Horizon National Corporation (“First Horizon”) (NYSE: FHN) and First Tennessee Bank National Association (“First Tennessee Bank”). Mr. Glass was elected Chairman of the Board of First Horizon effective January 1, 2004, and President and Chief Executive Officer of First Horizon in July 2002. Mr. Glass received his B.A. in Accounting from Harding University and graduated from Harvard Business School’s Advanced Management Program.
Kenneth S. Robinson, M.D., M.Div., age 56, has served as a director since May 2008 and serves as Chairman of the Nominating and Corporate Governance Committee and as a member of the Audit Committee. From 2003 through 2007, Dr. Robinson served in the cabinet of Tennessee Governor Phil Bredesen as Commissioner of Health, overseeing 3,500 state employees and a $548 million budget. From 1982 through 1991, Dr. Robinson taught and practiced internal medicine at Vanderbilt University School of Medicine, and from 1991 through 2003 he was an Assistant Dean at the University of Tennessee College of Medicine. Since 1991, he has served as Pastor and Chief Executive of St. Andrew AME Church. In 1998, Dr. Robinson was named one of the country's ten Community Health Leaders by the Robert Wood Johnson Foundation, and in 2000 he received the Community Builder Award from the national United Way of America. Dr. Robinson holds a B.A., cum laude, from Harvard University, a M.D. from Harvard Medical School and a Master of Divinity from Vanderbilt Divinity School.
Timothy R. G. Sear, age 73, was appointed as a director in October 2004 and currently serves on the Audit Committee and the Compensation Committee. Mr. Sear served as Chairman Emeritus of Alcon, Inc. until May 2010, having previously retired from the offices of President and Chief Executive Officer on September 30, 2004. Prior to serving as President and Chief Executive Officer of Alcon, Mr. Sear served as Executive Vice President for Alcon’s U.S. Operations from 1996 through 1997 and also as Executive Vice President for Alcon’s International Division from 1988 to 1996. Mr. Sear is a graduate of Manchester University in the UK and Copenhagen University, Denmark, and received an MBA in International Business from Indiana University. He is also a graduate of Harvard Business School’s Advanced Management Program. Mr. Sear previously served as a director of Sigma-Aldrich, Inc. (Nasdaq: SIAL) from 2005-2009.